Summary of symposium.
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001321:Autistic Disorder / Q000150:complications / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology / Q000652:urine; D001921:Brain / Q000503:physiopathology; D002027:Bufotenin / Q000652:urine; D002493:Central Nervous System Diseases / Q000150:complications; D004569:Electroencephalography; D005071:Evoked Potentials; D006801:Humans; D008607:Intellectual Disability / Q000150:complications; D007806:Language Disorders / Q000150:complications; D009069:Movement Disorders / Q000150:complications; D010640:Phenothiazines; D013888:Thiothixene / Q000627:therapeutic use; D014284:Triiodothyronine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010640:Phenothiazines; D014284:Triiodothyronine; D002027:Bufotenin; D013888:Thiothixene